U.S. Markets closed

Celldex (CLDX) Soars: Stock Adds 10% in Session

Zacks Equity Research

Celldex Therapeutics, Inc. CLDX was a big mover last session, as the company saw its shares rise nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 84% in the past one-month time frame.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Celldex currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.

Celldex Therapeutics, Inc. Price

Celldex Therapeutics, Inc. Price

Celldex Therapeutics, Inc. price | Celldex Therapeutics, Inc. Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider Abeona Therapeutics Inc. ABEO, which also has a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Celldex Therapeutics, Inc. (CLDX) : Free Stock Analysis Report
 
Abeona Therapeutics Inc. (ABEO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.